DE2001671C3 - Plyvalentes Mastits-Immunglobulin und dessen Verwendung bei der Bekämpfung der Mastits - Google Patents
Plyvalentes Mastits-Immunglobulin und dessen Verwendung bei der Bekämpfung der MastitsInfo
- Publication number
- DE2001671C3 DE2001671C3 DE2001671A DE2001671A DE2001671C3 DE 2001671 C3 DE2001671 C3 DE 2001671C3 DE 2001671 A DE2001671 A DE 2001671A DE 2001671 A DE2001671 A DE 2001671A DE 2001671 C3 DE2001671 C3 DE 2001671C3
- Authority
- DE
- Germany
- Prior art keywords
- staph
- growth
- aureus
- mastitis
- immunoglobulin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 108060003951 Immunoglobulin Proteins 0.000 title claims description 47
- 102000018358 immunoglobulin Human genes 0.000 title claims description 47
- 208000004396 mastitis Diseases 0.000 claims description 62
- 241000283690 Bos taurus Species 0.000 claims description 28
- 210000004369 blood Anatomy 0.000 claims description 20
- 239000008280 blood Substances 0.000 claims description 20
- 238000000034 method Methods 0.000 claims description 5
- 206010016654 Fibrosis Diseases 0.000 description 43
- 230000004761 fibrosis Effects 0.000 description 43
- 210000002966 serum Anatomy 0.000 description 31
- 238000011282 treatment Methods 0.000 description 31
- 244000005700 microbiome Species 0.000 description 28
- 241001465754 Metazoa Species 0.000 description 24
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 22
- 239000003242 anti bacterial agent Substances 0.000 description 20
- 229940088710 antibiotic agent Drugs 0.000 description 18
- 210000000481 breast Anatomy 0.000 description 15
- 210000004027 cell Anatomy 0.000 description 14
- 239000008267 milk Substances 0.000 description 14
- 235000013336 milk Nutrition 0.000 description 14
- 210000004080 milk Anatomy 0.000 description 14
- 239000000047 product Substances 0.000 description 13
- 239000000243 solution Substances 0.000 description 11
- 241000283707 Capra Species 0.000 description 10
- 206010030113 Oedema Diseases 0.000 description 10
- 238000002347 injection Methods 0.000 description 10
- 239000007924 injection Substances 0.000 description 10
- 210000002381 plasma Anatomy 0.000 description 10
- 230000004520 agglutination Effects 0.000 description 9
- 230000000521 hyperimmunizing effect Effects 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- 230000036039 immunity Effects 0.000 description 8
- 229940056360 penicillin g Drugs 0.000 description 8
- 241000588724 Escherichia coli Species 0.000 description 7
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 7
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 7
- 235000011130 ammonium sulphate Nutrition 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- 229930182555 Penicillin Natural products 0.000 description 6
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 6
- 241000589516 Pseudomonas Species 0.000 description 6
- 230000003115 biocidal effect Effects 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 229940049954 penicillin Drugs 0.000 description 6
- 239000002244 precipitate Substances 0.000 description 6
- 238000001556 precipitation Methods 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- ASXBYYWOLISCLQ-UHFFFAOYSA-N Dihydrostreptomycin Natural products O1C(CO)C(O)C(O)C(NC)C1OC1C(CO)(O)C(C)OC1OC1C(N=C(N)N)C(O)C(N=C(N)N)C(O)C1O ASXBYYWOLISCLQ-UHFFFAOYSA-N 0.000 description 5
- 241000194017 Streptococcus Species 0.000 description 5
- 229960002222 dihydrostreptomycin Drugs 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 208000015181 infectious disease Diseases 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 206010003694 Atrophy Diseases 0.000 description 4
- 241000193830 Bacillus <bacterium> Species 0.000 description 4
- 102000006395 Globulins Human genes 0.000 description 4
- 108010044091 Globulins Proteins 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 230000004523 agglutinating effect Effects 0.000 description 4
- 239000004599 antimicrobial Substances 0.000 description 4
- 230000037444 atrophy Effects 0.000 description 4
- ASXBYYWOLISCLQ-HZYVHMACSA-N dihydrostreptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](CO)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O ASXBYYWOLISCLQ-HZYVHMACSA-N 0.000 description 4
- 210000002615 epidermis Anatomy 0.000 description 4
- 108010074605 gamma-Globulins Proteins 0.000 description 4
- 230000003053 immunization Effects 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 241000191967 Staphylococcus aureus Species 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 239000000910 agglutinin Substances 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 238000000502 dialysis Methods 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 230000009036 growth inhibition Effects 0.000 description 3
- 238000002649 immunization Methods 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 102000009027 Albumins Human genes 0.000 description 2
- 108010088751 Albumins Proteins 0.000 description 2
- 102000002572 Alpha-Globulins Human genes 0.000 description 2
- 108010068307 Alpha-Globulins Proteins 0.000 description 2
- 241000194110 Bacillus sp. (in: Bacteria) Species 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 230000000845 anti-microbial effect Effects 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000006161 blood agar Substances 0.000 description 2
- 210000000601 blood cell Anatomy 0.000 description 2
- 244000309466 calf Species 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000007881 chronic fibrosis Effects 0.000 description 2
- 230000001112 coagulating effect Effects 0.000 description 2
- 229940127089 cytotoxic agent Drugs 0.000 description 2
- 239000008121 dextrose Substances 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 230000005802 health problem Effects 0.000 description 2
- 230000002949 hemolytic effect Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000036512 infertility Effects 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 210000003339 pole cell Anatomy 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- 238000011321 prophylaxis Methods 0.000 description 2
- 239000001509 sodium citrate Substances 0.000 description 2
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 2
- 238000002255 vaccination Methods 0.000 description 2
- CZWJCQXZZJHHRH-YCRXJPFRSA-N 2-[(1r,2r,3s,4r,5r,6s)-3-(diaminomethylideneamino)-4-[(2r,3r,4r,5s)-3-[(2s,3s,4s,5r,6s)-4,5-dihydroxy-6-(hydroxymethyl)-3-(methylamino)oxan-2-yl]oxy-4-hydroxy-4-(hydroxymethyl)-5-methyloxolan-2-yl]oxy-2,5,6-trihydroxycyclohexyl]guanidine;sulfuric acid Chemical compound OS(O)(=O)=O.OS(O)(=O)=O.OS(O)(=O)=O.CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](CO)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](N=C(N)N)[C@H](O)[C@@H](N=C(N)N)[C@H](O)[C@H]1O.CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](CO)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](N=C(N)N)[C@H](O)[C@@H](N=C(N)N)[C@H](O)[C@H]1O CZWJCQXZZJHHRH-YCRXJPFRSA-N 0.000 description 1
- JGSARLDLIJGVTE-UHFFFAOYSA-N 3,3-dimethyl-7-oxo-6-[(2-phenylacetyl)amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid Chemical compound O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-UHFFFAOYSA-N 0.000 description 1
- 101710186708 Agglutinin Proteins 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- 102000008946 Fibrinogen Human genes 0.000 description 1
- 108010049003 Fibrinogen Proteins 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 206010018910 Haemolysis Diseases 0.000 description 1
- 101710146024 Horcolin Proteins 0.000 description 1
- 240000008415 Lactuca sativa Species 0.000 description 1
- 101710189395 Lectin Proteins 0.000 description 1
- 101710179758 Mannose-specific lectin Proteins 0.000 description 1
- 101710150763 Mannose-specific lectin 1 Proteins 0.000 description 1
- 101710150745 Mannose-specific lectin 2 Proteins 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- 241001134418 Polemon Species 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 241000193985 Streptococcus agalactiae Species 0.000 description 1
- 240000004922 Vigna radiata Species 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000037006 agalactosis Effects 0.000 description 1
- 239000001166 ammonium sulphate Substances 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 230000003385 bacteriostatic effect Effects 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 229960005091 chloramphenicol Drugs 0.000 description 1
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 229960001162 dihydrostreptomycin sulfate Drugs 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 229960003276 erythromycin Drugs 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 229940012952 fibrinogen Drugs 0.000 description 1
- 229960001625 furazolidone Drugs 0.000 description 1
- PLHJDBGFXBMTGZ-WEVVVXLNSA-N furazolidone Chemical compound O1C([N+](=O)[O-])=CC=C1\C=N\N1C(=O)OCC1 PLHJDBGFXBMTGZ-WEVVVXLNSA-N 0.000 description 1
- 230000008588 hemolysis Effects 0.000 description 1
- 238000000760 immunoelectrophoresis Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 150000002605 large molecules Chemical class 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000003223 protective agent Substances 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 239000004627 regenerated cellulose Substances 0.000 description 1
- 230000002787 reinforcement Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 235000012045 salad Nutrition 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 239000008399 tap water Substances 0.000 description 1
- 235000020679 tap water Nutrition 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ZA69333 | 1969-01-17 | ||
| ZA691780 | 1969-03-13 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| DE2001671A1 DE2001671A1 (de) | 1970-07-30 |
| DE2001671B2 DE2001671B2 (de) | 1980-09-25 |
| DE2001671C3 true DE2001671C3 (de) | 1981-10-08 |
Family
ID=27130988
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE2001671A Expired DE2001671C3 (de) | 1969-01-17 | 1970-01-15 | Plyvalentes Mastits-Immunglobulin und dessen Verwendung bei der Bekämpfung der Mastits |
Country Status (16)
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL1019143C2 (nl) * | 2001-10-08 | 2003-04-09 | Nutricia Nv | Farmaceutisch product of voedingssupplement en daarbij te gebruiken tussenproduct. |
| RU2338375C2 (ru) * | 2006-09-04 | 2008-11-20 | Государственное образовательное учреждение высшего профессионального образования "Удмуртский государственный университет" | Способ хранения плазмы или сыворотки крови для получения иммуноглобулиновых и альбуминовых биопрепаратов |
-
1969
- 1969-12-26 IL IL33614A patent/IL33614A/en unknown
-
1970
- 1970-01-09 AT AT514671A patent/AT309134B/de not_active IP Right Cessation
- 1970-01-14 MT MT639A patent/MTP639B/xx unknown
- 1970-01-14 CH CH47670A patent/CH560543A5/de not_active IP Right Cessation
- 1970-01-15 DE DE2001671A patent/DE2001671C3/de not_active Expired
- 1970-01-15 NO NO70145A patent/NO130179B/no unknown
- 1970-01-16 CA CA072,282A patent/CA954045A/en not_active Expired
- 1970-01-16 BE BE744515D patent/BE744515A/xx not_active IP Right Cessation
- 1970-01-16 FR FR7001552A patent/FR2034472B1/fr not_active Expired
- 1970-01-16 ES ES375511A patent/ES375511A1/es not_active Expired
- 1970-01-16 DK DK19270AA patent/DK128981B/da unknown
- 1970-01-16 IE IE62/70A patent/IE33944B1/xx unknown
- 1970-01-16 NL NL7000637.A patent/NL164746C/xx not_active IP Right Cessation
- 1970-01-17 IT IT47859/70A patent/IT1044200B/it active
- 1970-01-17 OA OA53835A patent/OA03892A/xx unknown
- 1970-01-19 GB GB1297011D patent/GB1297011A/en not_active Expired
Also Published As
| Publication number | Publication date |
|---|---|
| NO130179B (enrdf_load_stackoverflow) | 1974-07-22 |
| NL7000637A (enrdf_load_stackoverflow) | 1970-07-21 |
| DK128981B (da) | 1974-08-05 |
| IT1044200B (it) | 1980-03-20 |
| IL33614A (en) | 1973-08-29 |
| CA954045A (en) | 1974-09-03 |
| ES375511A1 (es) | 1973-04-16 |
| NL164746C (nl) | 1981-02-16 |
| MTP639B (en) | 1970-07-22 |
| DE2001671A1 (de) | 1970-07-30 |
| CH560543A5 (enrdf_load_stackoverflow) | 1975-04-15 |
| AT309134B (de) | 1973-08-10 |
| FR2034472B1 (enrdf_load_stackoverflow) | 1974-03-22 |
| GB1297011A (enrdf_load_stackoverflow) | 1972-11-22 |
| FR2034472A1 (enrdf_load_stackoverflow) | 1970-12-11 |
| OA03892A (fr) | 1975-08-14 |
| IE33944L (en) | 1970-07-17 |
| DK128981C (enrdf_load_stackoverflow) | 1975-01-20 |
| NL164746B (nl) | 1980-09-15 |
| DE2001671B2 (de) | 1980-09-25 |
| BE744515A (fr) | 1970-07-01 |
| IE33944B1 (en) | 1974-12-11 |
| IL33614A0 (en) | 1970-02-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE3689717T2 (de) | Einen spezifischen Antikörper enthaltender Stoff aus Eiern, Verfahren zu dessen Herstellung und seine Anwendung. | |
| DE69322624T2 (de) | Präparat zur behandlung und verhütung von bakteriellen infektionen,das chlordioxyd enthalt | |
| DE69722217T2 (de) | Verewndung von hyperimmunisierte milch und/oder ei zur behandlung von magen-darm verletzungen | |
| DE69715259T3 (de) | Intramammäre tierarzneimittel ohne antiinfektiöse wirkstoffe | |
| DE69711661T2 (de) | Micrococcin antibiotika zur prävention und therapie der mastitis | |
| DE3888504T2 (de) | Behandlung von Mastitis und Appliziereinrichtung dafür. | |
| DE2542792A1 (de) | Verfahren zur erhoehung der antikoerpermenge in der milch von milchabsondernden rindern | |
| DE69232338T2 (de) | Benzopyranphenolderivate zur Anwendung als bakterienhemmende, antivirale und wundheilende Mittel | |
| US4670263A (en) | Nontoxic, germicide, and healing compositions | |
| DE2458327A1 (de) | Rinder-immunoglobulin-isolierungsverfahren | |
| DE1810438A1 (de) | Prophylaktisches oder therapeutisches Praeparat | |
| EP0338229A1 (de) | Präparat mit Antikörperaktivität und breitem Wirkungsspektrum, daraus bestehende oder diese enthaltende Mittel und deren Verwendung zur Behandlung von bakteriell oder toxin-bedingten Erkrankungen und zur Bekämpfung von Protozoen | |
| US3917818A (en) | Treatment of mastitis in cows, the product for this treatment and to the production of said product | |
| CH651210A5 (de) | Verfahren zur herstellung einer antikoerper enthaltenden milch zur bekaempfung bakterieller infektionen des magen-darm-traktes. | |
| DE68906054T2 (de) | Hyperimmunizierte milch gegen bluthochdruck. | |
| DE69128781T2 (de) | Zusammensetzung und methode zur immunstimulierung in säugetieren | |
| DE2409862B2 (de) | Verwendung einer oral applizierbaren Immunoglobulinkombination | |
| DE69002024T2 (de) | Bioaktive Laktoferrin Derivate. | |
| DE2001671C3 (de) | Plyvalentes Mastits-Immunglobulin und dessen Verwendung bei der Bekämpfung der Mastits | |
| DE2620287A1 (de) | Verfahren zur wachstumsfoerderung von tieren | |
| AT300193B (de) | Verfahren zur Herstellung von Mastitis-Immunoglobulin | |
| DE2334376A1 (de) | Immunologisches produkt, seine verwendung und verfahren zu seiner herstellung | |
| DE2421084A1 (de) | Idfidobakterien enthaltendes praeparat | |
| DE19912439C2 (de) | Killertoxine aus Killerhefen zur pharmazeutischen Verwendung | |
| DE2728806A1 (de) | Auf oralem wege einzunehmender antiparasitaerer impfstoff, verfahren zu dessen herstellung und anwendungsmethode des impfstoffs bei saeugetieren |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C3 | Grant after two publication steps (3rd publication) | ||
| 8339 | Ceased/non-payment of the annual fee |